NVasc Overview
- Year Founded
-
2019
- Status
-
Private
- Latest Deal Type
-
Later Stage VC
- Investors
-
4
NVasc General Information
Description
Developer of a biopharmaceutical company intended to focus on treating blindness. The company develops therapy that treats blindness through choroidal and retinal revascularization, specifically targeting issues in the retina and choroid, enabling the healthcare sector to help patients maintain and restore vision by improving blood flow to these tissues.
Contact Information
Corporate Office
- 26871 Carranza Drive
- Mission Viejo, CA 92691
- United States
Corporate Office
- 26871 Carranza Drive
- Mission Viejo, CA 92691
- United States
NVasc Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC | 04-Nov-2024 | Completed | Startup | |||
| 3. Early Stage VC (Series A2) | 01-Nov-2019 | Completed | Startup | |||
| 2. Early Stage VC | $1M | $1M | Completed | Startup | ||
| 1. University Spin-Out | 01-Jan-2019 | Completed | Startup |
NVasc Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A-2 | ||||||||
| Series A-1 |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
NVasc Patents
NVasc Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026006563-A1 | Long-lasting lif proteins and formulations | Pending | 27-Jun-2024 |
NVasc Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Mitsui Global Investment | Venture Capital | Minority | ||
| Retinal Degeneration Fund | Not-For-Profit Venture Capital | Minority | ||
| Kairos Ventures | Venture Capital | Minority | ||
| University of California, San Diego | University |
NVasc FAQs
-
When was NVasc founded?
NVasc was founded in 2019.
-
Where is NVasc headquartered?
NVasc is headquartered in Mission Viejo, CA.
-
What industry is NVasc in?
NVasc’s primary industry is Drug Discovery.
-
Is NVasc a private or public company?
NVasc is a Private company.
-
What is NVasc’s current revenue?
The current revenue for NVasc is .
-
How much funding has NVasc raised over time?
NVasc has raised $3M.
-
Who are NVasc’s investors?
Mitsui Global Investment, Retinal Degeneration Fund, Kairos Ventures, and University of California, San Diego have invested in NVasc.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process